These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 30229902

  • 1. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.
    Zhang M, Cong Q, Zhang XY, Zhang MX, Lu YY, Xu CJ.
    J Cell Physiol; 2019 May; 234(5):6361-6370. PubMed ID: 30229902
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, Ingersoll SB, Turkson J.
    Oncogene; 2012 May 03; 31(18):2309-22. PubMed ID: 21909139
    [Abstract] [Full Text] [Related]

  • 6. Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma.
    Lu H, Lu Y, Xie Y, Qiu S, Li X, Fan Z.
    JCI Insight; 2019 Oct 03; 4(19):. PubMed ID: 31578313
    [Abstract] [Full Text] [Related]

  • 7. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer.
    Zhao J, Tan W, Zhang L, Liu J, Shangguan M, Chen J, Zhao B, Peng Y, Cui M, Zhao S.
    Biochem Pharmacol; 2021 Aug 03; 190():114536. PubMed ID: 33794187
    [Abstract] [Full Text] [Related]

  • 8. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A.
    Clin Cancer Res; 2011 Apr 15; 17(8):2350-60. PubMed ID: 21220476
    [Abstract] [Full Text] [Related]

  • 9. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
    Woolbright BL, Choudhary D, Mikhalyuk A, Trammel C, Shanmugam S, Abbott E, Pilbeam CC, Taylor JA.
    Mol Cancer Ther; 2018 Sep 15; 17(9):2004-2012. PubMed ID: 29907593
    [Abstract] [Full Text] [Related]

  • 10. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
    Qin S, Li Y, Cao X, Du J, Huang X.
    Biosci Rep; 2017 Feb 28; 37(1):. PubMed ID: 27884977
    [Abstract] [Full Text] [Related]

  • 11. PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma.
    Kitamura S, Yamaguchi K, Murakami R, Furutake Y, Higasa K, Abiko K, Hamanishi J, Baba T, Matsumura N, Mandai M.
    Cancer Sci; 2021 Nov 28; 112(11):4627-4640. PubMed ID: 34464482
    [Abstract] [Full Text] [Related]

  • 12. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
    Wu YH, Chang TH, Huang YF, Chen CC, Chou CY.
    Oncotarget; 2015 Sep 15; 6(27):23748-63. PubMed ID: 26087191
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z, Zhang SL, Hu X, Tam KY.
    Eur J Pharmacol; 2018 Nov 05; 838():41-52. PubMed ID: 30213498
    [Abstract] [Full Text] [Related]

  • 14. p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer.
    Han CY, Patten DA, Lee SG, Parks RJ, Chan DW, Harper ME, Tsang BK.
    Mol Carcinog; 2019 Nov 05; 58(11):2161-2174. PubMed ID: 31486135
    [Abstract] [Full Text] [Related]

  • 15. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells.
    Sun H, Wang H, Wang X, Aoki Y, Wang X, Yang Y, Cheng X, Wang Z, Wang X.
    Theranostics; 2020 Nov 05; 10(15):6928-6945. PubMed ID: 32550913
    [Abstract] [Full Text] [Related]

  • 16. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W, Chen Y, Zhu KY, Deng H, Wu T, Wang J.
    Biol Pharm Bull; 2017 Aug 01; 40(8):1306-1313. PubMed ID: 28515374
    [Abstract] [Full Text] [Related]

  • 17. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY, Jiao DM, Wang J, Hu H, Tang X, Chen J, Mou H, Lu W.
    Oncotarget; 2016 Apr 26; 7(17):24510-26. PubMed ID: 27014910
    [Abstract] [Full Text] [Related]

  • 18. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H, Fang L, Jiang J, Kuang Y, Wang B, Shang X, Han P, Li Y, Liu M, Zhang Z, Li P.
    Cell Death Dis; 2018 Oct 30; 9(11):1103. PubMed ID: 30375398
    [Abstract] [Full Text] [Related]

  • 19. Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.
    Granados ML, Hudson LG, Samudio-Ruiz SL.
    PLoS One; 2015 Oct 30; 10(9):e0136893. PubMed ID: 26351843
    [Abstract] [Full Text] [Related]

  • 20. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR, Schorl C, Yano N, Romano N, Kim KK, Singh RK, Moore RG.
    J Ovarian Res; 2016 May 17; 9(1):28. PubMed ID: 27184254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.